Millennium Management LLC Sells 718,857 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Millennium Management LLC cut its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 76.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 215,531 shares of the biotechnology company's stock after selling 718,857 shares during the period. Millennium Management LLC owned about 0.14% of Heron Therapeutics worth $330,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HRTX. J. Goldman & Co LP bought a new position in shares of Heron Therapeutics in the 4th quarter valued at $413,000. Focus Partners Wealth bought a new position in shares of Heron Therapeutics in the 4th quarter valued at $31,000. Cornerstone Select Advisors LLC bought a new position in shares of Heron Therapeutics in the 4th quarter valued at $78,000. Bridgeway Capital Management LLC bought a new position in shares of Heron Therapeutics in the 4th quarter valued at $459,000. Finally, Bank of America Corp DE raised its position in Heron Therapeutics by 9.5% during the 4th quarter. Bank of America Corp DE now owns 1,046,790 shares of the biotechnology company's stock worth $1,602,000 after purchasing an additional 90,862 shares during the last quarter. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Price Performance

Shares of HRTX traded down $0.08 during trading hours on Friday, hitting $1.93. The stock had a trading volume of 748,067 shares, compared to its average volume of 2,236,826. The firm has a 50 day simple moving average of $2.02 and a 200-day simple moving average of $1.89. The firm has a market capitalization of $294.45 million, a P/E ratio of -10.72 and a beta of 1.16. Heron Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $3.73.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million. Equities analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on HRTX shares. Needham & Company LLC reaffirmed a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a research report on Friday, April 11th. HC Wainwright started coverage on Heron Therapeutics in a research report on Monday, June 9th. They set a "buy" rating and a $6.00 target price for the company. Finally, Wall Street Zen upgraded Heron Therapeutics from a "hold" rating to a "buy" rating in a report on Friday, June 6th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.